Actively Recruiting
Pulmonary Thromboembolism in Cancer Patients: Early Rule-out From the Emergency Department
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-07
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating pulmonary thromboembolism (PTE) in cancer patients, focusing on those diagnosed either symptomatically or incidentally during cancer follow-up. The study aims to compare several scoring systems used by physicians to identify patients at low risk of serious complications within 30 days of PTE diagnosis. This could help safely discharge low-risk patients early from the emergency department, reducing lengthy hospital stays and their impact on health and psychological well-being. This observational study collects data at emergency department admission, recording information needed to calculate six different risk scores. Patients will receive usual care based on physician judgment, with no experimental treatments involved. Participants will be followed up by phone 30 days after their emergency visit to assess health status and record any major adverse events such as death, respiratory failure, or rehospitalization. The study includes both retrospective data collection and prospective enrollment over approximately three years. Participants will provide informed consent and contribute data during their emergency department visit, which takes about five minutes to collect. Follow-up phone calls last around one minute. Researchers will analyze the performance of the prognostic scores in predicting 30-day outcomes using hospital records and statistical methods. Safety monitoring focuses on identifying patients at low risk who can be discharged early without increased risk of serious complications. Overall participation lasts from initial emergency department contact through a 30-day follow-up period.
CONDITIONS
Brief Title
Pulmonary Thromboembolism in Cancer Patients: Early Rule-out From the Emergency Department
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of pulmonary embolism (symptomatic or incidental)
- Active onco-haematological disease under oncological, haematological, or metastatic care
- Provided informed consent to participate in the study
You will not qualify if you...
- Patients returning to the emergency department for complications related to previously diagnosed pulmonary embolism
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) at the Emergency Department
Duration - Up to initial emergency department stay
Participants diagnosed with pulmonary embolism during emergency department admission will undergo diagnostic assessments according to clinical practice.
1 to 2 visits during emergency department stay
Duration - 30 days
Participants will be observed for major adverse events including death, respiratory failure, or re-hospitalisation for 30 days following diagnosis.
Follow-up assessments through medical records and possible clinical visits as needed
Trial Site Locations
Total: 1 location
1
Eleonora Tubertini
Bologna, Italy, 40138
Actively Recruiting
Research Team
E
Eleonora Tubertini, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here